Recent News
Immunis Announces Double Win from the 2024 Global Health and Pharma Awards
Immunis Inc., a trailblazer in secretome therapeutics for age-related diseases and immune dysfunction, is proud to announce its remarkable double-win from the 2024 Global Health and Pharma (GHP) awards. The company has been honored with two prestigious awards: "Innovation Award in Age-Related Disease R&D" and "Immune Dysfunction Treatment Developers of the Year." These accolades represent the company’s dedication to pioneering solutions for some of the most challenging age-related health concerns including muscle atrophy and metabolic decline.
Immunis Chairman Dr. Hans Keirstead to Present at the Festival of Biologics in San Diego
Immunis Inc., a groundbreaking biotech developing novel secretome therapeutics for age-related diseases and immune dysfunction, is thrilled to announce that its esteemed Chairman, Dr. Hans Keirstead, will be presenting at the Festival of Biologics in San Diego. This renowned conference serves as a global platform for leading minds in the biologics sector to share breakthroughs, foster collaborations, and discuss the future of biotechnology and medicine.
Immunis Discusses with Experts Why the Immune System is the Key to Human Healthspan
Immunis Inc., a leading biotech in secretome therapeutics addressing age-related diseases and immune dysfunction, is proud to unveil its latest video project entitled “Unlocking Lifelong Vitality: Immunis Aims to Supercharge Our Immune System for a Healthier Future.” This project features insights from world-renowned leaders in human health including Dr. Hans Keirstead, Jane Metcalfe, Dr. Peter Diamandis and Dr. Micah Drummond, who share a vision of revolutionizing human healthspan through the immune system.
Immunis Inc., a private biotechnology company developing novel secretome therapeutics for age-related diseases and immune dysfunction, announces the peer-reviewed publication of research by Immunis and the University of Utah’s Professor Micah Drummond. The study, published in Aging Cell, is entitled “Stem cell secretome-treatment improves whole-body metabolism, reduces adiposity and promotes skeletal muscle function in aged mice.” The research examines the effects of Immunis’ investigational secretome on metabolism, fat and skeletal muscle in aged mouse models.
Immunis Chairman Dr. Hans Keirstead to Present Abundance360 Moonshot
Immunis, Inc., a private biotech company developing an innovative secretome for age-related diseases and immune dysfunction, announces that its Chairman, Dr. Hans Keirstead, will present at the annual Abundance360 in Los Angeles. Dr. Peter Diamandis is the world-renown entrepreneur and mastermind behind Abundance360, which fosters collaboration between prominent figures in space, technology, education, venture capital and longevity research.
Immunis, Inc., a private biotech developing innovative cellular secretomes to address age-related diseases and immune dysfunction, shares that its Chief Business Officer, Mark Cabato, CFA will be speaking at the Global Life Science Partnering and Investor Conference (GPIC) in San Diego. GPIC stands as a premier international networking event, uniting top-level executives, financiers, venture capitalists, and business development experts from foremost pharmaceutical and biotech firms.
Immunis Chairman Dr. Hans Keirstead to Present at the 2024 BIO CEO and Investor Conference
Immunis, Inc., a private biotech company developing novel secretome therapeutics for age-related diseases and immune dysfunction, announces that its esteemed Chairman, Dr. Hans Keirstead, will present at the 2024 BIO CEO & Investor Conference in New York City (February 26-27). Recognized as one of the largest investor conferences in the country, the event highlights established and emerging publicly traded and private biotech companies. The conference serves as a crucial platform for international investors, industry analysts, and biotechnology executives to engage in meaningful dialogue and explore future investments in the biomedical industry.
Immunis Chairman Dr. Hans Keirstead is an Invited Speaker at the 2024 Brain Trust Conference
Immunis, Inc., a private biotech company revolutionizing cellular secretome therapeutics, is proud to announce that its Chairman, Dr. Hans Keirstead, will present at the exclusive 13D Brain Trust Conference in the Bahamas. Brain Trust is a highly exclusive, invite-only event covering artificial intelligence, global technological advancements, innovative biotechnology, and unique investment opportunities. Like its name, the Brain Trust Conference invites the world’s greatest minds to realize their visions for the world.
Immunis Chairman Dr. Hans Keirstead Presents at the Longevity Investors Lunch in Davos [Photos]
Immunis, Inc., a private biotech and a pioneering force in cellular secretome therapeutics, is delighted to share some photos from the 2024 Longevity Investors Lunch In Davos, Switzerland (hosted by Longevity Investors Conference). This prestigious event brings together prominent leaders in biotechnology, investment, and innovation to discuss recent advancements in the longevity sector. Immunis, Chairman, Dr. Hans Keirstead, was an invited speaker and panelist for the conference.
Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, presents a one-of-a-kind film with world-renown longevity innovators who examine the future of aging and human healthspan. Immunis was honored to host esteemed interviewees Dr. Peter Diamandis, Dr. Hans Keirstead, Dr. Daniel Kraft, and Jane Metcalfe, who all share the common goal of revolutionizing human health.
Immunis Chairman Dr. Hans Keirstead to Speak at the Longevity Investors Lunch in Davos
Immunis, Inc., a private biotech and a pioneering force in cellular secretome therapeutics, is thrilled to announce that its Chairman, Dr. Hans Keirstead, is an invited speaker at the exclusive Longevity Investors Lunch in Davos, Switzerland (hosted by Longevity Investors Conference). This prestigious event is celebrated for its role in uniting distinguished figures in biotechnology, investment, and research to delve into the most recent advancements and trends in the longevity sector. The conference will emphasize the importance of innovative therapeutic approaches in aging and longevity, showcasing cutting-edge developments in cellular therapies, genomics, and age-related disease management.
Immunis Chairman Dr. Hans Keirstead to Present at the 2024 Biotech Showcase
Immunis, Inc., a private biotech transforming the field of cellular secretome therapeutics, is excited to reveal that its esteemed Chairman, Dr. Hans Keirstead, will be a featured speaker at the upcoming 2024 Biotech Showcase in San Francisco. The Biotech Showcase is a distinguished event, renowned for bringing together global leaders in biotechnology, pharmaceuticals, and finance to explore the industry’s latest trends and innovations. This year's conference focuses on drug development in areas including oncology, cell and gene therapy, and rare diseases.
Immunis Wins Two BASA Biotech Awards: “Best Small Business” and “Best Entrepreneur”
Immunis, Inc., a private biotechnology company developing innovative secretome therapeutics for age and disease-related immune disfunction, is honored to win two 2023 Best of America Small Business Awards (BASA). Not only was Immunis recognized as the “Best Small Business” in biotechnology, but Immunis’ Chairman, Dr. Hans Keirstead, was also awarded “Best Entrepreneur.” These accolades are a testament to the company's innovation, excellence, and leadership in the competitive and rapidly evolving field of biotechnology.
Immunis Chairman Dr. Hans Keirstead is Honored As One of OCBJ’s OC500
Immunis, Inc., a leading private biotech at the forefront of innovative immunomodulatory secretome therapeutics for age-related diseases, is proud to announce that its Chairman, Hans Keirstead, Ph.D., has once again been named one of Orange County Business Journal’s OC 500 for 2023. Selection for this honor is based on a comprehensive merit assessment, recognizing top executives, government leaders, philanthropists, and other prominent civic figures who have made significant contributions to the Orange County business community.
Immunis is a Finalist for Best of America Small Business Awards – Vote for Us!!!
Immunis, Inc., a private biotech revolutionizing cellular secretome therapies to address age and disease-related immune decline, is thrilled to announce its selection as a finalist for the Best of America Small Business Awards (BASA). The BASA awards celebrate the resilience, creativity, and indispensable role that small businesses play in enhancing economic growth and social responsibility.
Immunis Chairman Dr. Hans Keirstead to Present at BIO Europe Conference in Germany
Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, proudly announces that its Chairman, Dr. Hans Keirstead, will present at BIO Europe in Germany. With over 5,000 attendees, the conference gathers key stakeholders and thought leaders in the biotechnology space, serving as an exceptional platform for sharing breakthroughs, fostering collaborations, and charting the future of biomedicine.
Immunis Chief Business Officer Mark Cabato to Deliver Keynote at the Drug Discovery Strategic Summit
Immunis, Inc., a leading biotechnology company forging innovative cellular secretome therapies for age and disease-related immune decline, is delighted to announce that its Chief Business Officer, Mark Cabato, will be a keynote speaker at this year's Drug Discovery Strategic Summit.
Immunis Chairman Dr. Hans Keirstead to Present at Innovative Therapies Days in France
Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, is pleased to announce that its Chairman, Dr. Hans Keirstead, will be taking center stage at the prestigious Innovative Therapies Days conference in Besançon, France. Innovative Therapies Days is a premier event in medical innovation, showcasing presentations from esteemed clinicians, scientists, and industry partners. This year, the conference will focus on cutting-edge technologies using stem cells, cellular secretomes, CAR-T cells, and much more.
Immunis Welcomes UC Berkeley Professor Irina Conboy to the Scientific Advisory Board
Immunis, Inc., a private biotech company creating novel cellular secretome therapies for age and disease-related immune decline, is delighted to have Professor Irina Conboy on its Scientific Advisory Board. Dr. Conboy is a Professor of Bioengineering at UC Berkeley, investigator at the Quantitative Biology Institute, and Editor in Chief of Rejuvenation Research. Her groundbreaking studies have unveiled critical paradigms on the effects of age-related and pathological changes on tissue maintenance and repair, setting the stage for novel therapeutic interventions.
Immunis Chairman Dr. Hans Keirstead to Present at the Festival of Biologics in Basel
Immunis, Inc., a private biotech developing innovative cellular secretome therapies for age and disease-related immune decline, is thrilled to announce that its Chairman, Dr. Hans Keirstead, will be taking center stage at the prestigious Festival of Biologics in Basel, Switzerland. The Festival of Biologics is a pivotal meeting for the life science community, encompassing the entire spectrum of biologics, from drug discovery and development to manufacturing, clinical trials, and commercialization. Dr. Keirstead's presence supports Immunis' position at the forefront of biotechnological research and dedication to enhancing global health through innovation.
Immunis Wins Corporate LiveWire’s 2023 “Innovation and Excellence Award”
Immunis, Inc., a private biotech creating novel cellular secretome therapies for age and disease-related immune decline, was bestowed Corporate LiveWire’s prestigious “Innovation and Excellence Award.” Corporate LiveWire is highly regarded in the business world, acknowledging the stellar performance of leading companies with technological innovation. Immunis' cutting-edge research and transformative secretome technologies have undoubtedly set the company apart as a trailblazer in biomedicine.
Immunis Chairman Dr. Hans Keirstead to Present at Advanced Therapies in Portugal
Immunis, Inc., a private biotech company developing novel cellular secretome therapies for age and disease-related immune decline, is delighted that its Chairman, Dr. Hans Keirstead, will present at the Advanced Therapies Conference in Portugal. The Advanced Therapies Conference is a premier gathering of thought leaders and pioneers from around the globe, engaging in discourse on the latest innovations in therapeutic research.
Immunis is a Finalist for the High Tech Award for “Best Emerging Technology Company”
Immunis, Inc., a private biotech and a leading innovator in cellular secretome therapies for age and disease-related immune decline, is honored to be selected as a finalist for the "Best Emerging Technology Company" by the Octane High Tech Awards (HTA). The HTA awards recognize exceptional technology companies that have made significant contributions to their respective industries through innovation, leadership, and outstanding achievements.
Immunis Chairman Dr. Hans Keirstead to Speak at the Ending Age-Related Diseases Summit
Immunis, Inc., a private biotechnology company pioneering cellular secretome therapies for age and disease-related immune decline, is excited to announce that its Chairman, Dr. Hans Keirstead, will be a panelist at Lifespan.io’s Ending Age-Related Diseases Summit. The summit in New York brings together the world's foremost experts in the aging field to discuss the cutting-edge developments in longevity research.
Immunis, Inc., a private biotech company developing a novel cellular secretome therapy for age and disease-related immune decline, is thrilled to announce that it has received unanimous approval from the Data Safety and Monitoring Board (DSMB) to proceed enrolling the next cohort of patients for its Phase 1/2a clinical trial.
Immunis Nominated for Prix Galien Award for “Best Startup”
Immunis, Inc., a private biotech company pioneering a novel secretome-based therapy for age and disease-related immune decline, is thrilled to announce its nomination for the prestigious Prix Galien Award for "Best Startup.
The (Secret)ome to Longevity – Summary #3
A healthy immune system: the ultimate balancing act Our immune system is the intricate network of cells, tissues, and their secretions that help the body fight illness and infection. The immune system is comprised of two branches, the innate and the adaptive immune responses. The innate immune response is the first line of defense that immediately works to prevent the spread of pathogens and tumors,1 while the adaptive immune response is a specialized, secondary response for clearing specific pathogens.2
Immunis Releases Video Showcasing its Advanced Biotech Infrastructure
Immunis, Inc., a private biotech company developing an innovative secretome therapeutic for age and disease-related immune decline, shares a video featuring the leading edge-capabilities of its infrastructure. Immunis invites everyone to learn about the significant coordination efforts of turning the vision of IMMUNA into a potentially life-changing treatment.
The (Secret)ome to Longevity – Summary #2
A healthy immune system: the ultimate balancing act The immune system encompasses innate and adaptive immune responses, both of which are crucial in maintaining our health. The innate immune response is the first line of defense that quickly works to prevent the spread of pathogens and tumors.1 The adaptive immune response is more sophisticated and specialized secondary response that clears specific pathogens and provides long-lasting immunity.2 The efficacy of these two systems depends on balanced inflammatory and anti-inflammatory responses referred to as immunomodulation.
The (Secret)ome to Longevity – Summary # 1
A healthy immune system: the ultimate balancing act The immune system is comprised of innate and adaptive immune responses, both of which are crucial in maintaining our health. The innate immune response is the first line of defense that immediately works to prevent the spread of pathogens and tumors.1 The adaptive immune response is a more sophisticated, secondary response that is specialized to clear specific pathogens and provide long-lasting immunity.2
The (Secret)ome to Longevity – Full Length
Our immune system is the foundation of our health. It is the intricate network of cells, tissues, and their secretions that help the body fight illness and infection. The immune system is comprised of two major branches, the innate and the adaptive immune responses, both of which are crucial in maintaining our health. The innate immune response is the first line of defense that immediately works to prevent the spread of pathogens and tumors.1 The adaptive immune response is a more sophisticated, secondary response that is highly specialized for clearance of specific pathogens and can provide long-lasting immunity against these microscopic invaders.2
Immunis Chairman Dr. Hans Keirstead to Present at the BIO International Convention
Immunis, Inc., a private biotech company creating a novel therapeutic for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., will be a featured presenter at the renowned BIO International Convention. This convention provides inspiring contributions to the field of regenerative medicine by shedding light on novel approaches to combat disease.
Immunis Chairman Dr. Hans Keirstead to Present at the 5th Age-Related Disease Therapeutics Summit
Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., will speak at the highly anticipated 5th Age-Related Disease Therapeutics Summit. This event brings together the brightest minds in longevity research, fostering an environment of collaboration, learning, and progress in ameliorating age-related diseases.
Immunis Appoints Mark Cabato as Chief Business Officer
Immunis, Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, is thrilled to appoint Mark Cabato as Chief Business Officer. Mark is a distinguished biotech executive and business leader with over 20 years of experience in the healthcare industry. He spent 15 years at Sumitomo Mitsui Banking Corporation, where he evolved in his role of Global Pharma Banker to Director of Healthcare Corporate and Investment Banking.
Immunis Awarded “Best Immune Deficit Treatment Development” by Global Health and Pharma Magazine
Immunis, Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, received the 2023 Global Health and Pharma Biotechnology Award for “Best Immune Deficit Treatment Development.” Global Health and Pharma (GHP) is an online magazine that showcases the latest innovations in biotech. All nominated companies were judged in-house by a select research team, thus ensuring all awards were merit-based.
Immunis Appoints Neil Sahota as Chief Artificial Intelligence Officer
Immunis, Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, has appointed Neil Sahota as its Chief Artificial Intelligence (AI) Officer. AI is a tool that is transforming the way businesses and scientists integrate information, conduct data analysis, and make informed decisions on how to optimize growth. For over 20 years, Neil has inspired AI modernization through technology-based business strategies and has been successful in helping businesses become leaders in the digital future. Immunis is confident that Neil will guide the company to unlock the considerable potential of AI in biotech.
Immunis Chairman Dr. Hans Keirstead to Present at Abundance360
Chairman of the Immunies Inc., a provate biotechnology company, Hans Keirstead, Ph.D., will present in the annual confernce at Abundance360 in Los Angeles.
Immunis Research Scientist Dr. Scott Greilach to Present at the Festival of Biologics in San Diego
Immunis, Inc., a private biotechnology company with a novel treatment for age and disease-related immune deficits, announces that its Research Scientist, Scott Greilach, Ph.D., will present at the Festival of Biologics in San Diego. With hundreds of world-class speakers, this three-day conference dissects the infrastructure of innovative biologics including discovery, development, manufacturing, pricing and market access. The conference’s goal is to harness the expertise from individuals in pharma, biotech and academic sectors to tackle the commercial challenges of bringing new therapies to market.
Immunis Chairman Dr. Hans Keirstead to Present at NextMed Health
Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., will present a keynote at the annual NextMed Health conference in San Diego. This premier event was founded by Dr. Daniel Kraft, who has over 25 years of experience as an inventor, innovator, entrepreneur, investor and renowned speaker. Dr. Kraft’s expertise in the field of stem cell-based therapies also makes him an invaluable asset as Board Member of Immunis Inc.
Immunis, Inc., a private biotechnology company with an innovative treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., will present at the annual Global Life Science Partnering and Investor Conference in La Jolla, California.
Immunis Chairman Dr. Hans Keirstead to Present at 2023 BIO CEO and Investor Conference
Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., will present at the 2023 BIO CEO and Investor Conference in New York. Dr. Keirstead is thrilled to discuss the recent milestones of Immunis’ Phase 1/2a clinical trial, which applies an investigational secretome product, STEM, in participants with muscle atrophy related to knee osteoarthritis.
Immunis Recruits Individuals with Muscle Atrophy for Phase 1/2a Clinical Trial
Immunis Inc. is a private biotechnology company recruiting participants between the ages of 50-75 with muscle atrophy related to knee osteoarthritis for its Phase 1/2a clinical trial. The trial will assess the safety and tolerability of Immunis’ investigational secretome product designed to benefit immune system modulation and health.
Immunis Inc. Featured by DelveInsight for Recent Developments in Knee Osteoarthritis Research
Immunis Inc. was featured by DelveInsight Business Research LLP as one of the six companies with recent developments in researching a treatment for knee osteoarthritis. DelveInsight is a leading Business Consultant and Market Research Firm that examines the innovative landscape of the healthcare industry to inform decision-makers on critical issues and opportunities. For more information about the article, read here.
Immunis Chairman Dr. Hans Keirstead to Present at the 2023 Biotech Showcase
Immunis, Inc., a private biotech company generating a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., will present at the annual Biotech Showcase in San Francisco. Dr. Keirstead will share the latest advancements of Immunis’ investigational secretome product, STEM, highlighting the Phase 1/2a clinical trial's first-in-human injection milestone.
Immunis Featured in Lifespan.io
Immunis Inc.'s press release announcing the first-in-human injection of STEM was highlighted by Lifespan.io, an online news source for breakthrough technologies and scientific discoveries in aging and longevity. The article is entitled "Immunis Begins Clinical Trial of Stem Cell Secretome." The high-level, scientific content for Lifespan.io is supported by The Lifespan Extension Advocacy Foundation (LEAF), a 501(c)(3) non-profit organization promoting fundamental research on aging and age-related diseases, as well as educating the public on the possibility of preventing age-related diseases.
Immunis Announces First-in-Human Injection of Secretome Product for Age-Related Muscle Atrophy
Immunis, Inc., a private biotech company developing an innovative treatment for age and disease-related immune decline, announces its first-in-human injection of IMM01-STEM for its STEM-MYO Phase 1/2a clinical trial. The goal is to assess the safety and tolerability of Immunis’ investigational stem cell secretome product, IMM01-STEM, in patients with muscle atrophy related to knee osteoarthritis, an inflammatory disease contributing to age-related disability. Immunis is actively recruiting patients for the trial in collaboration with the California Institute of Regenerative Medicine (CIRM) Alpha Clinic.
Immunis Chairman Dr. Hans Keirstead Appointed to Board of Directors of the Human Immunome Project
Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., was appointed to the Board of Directors of the Human Immunome Project. The Human Immunome Project is a global initiative that combines breakthrough advances in biomedicine and artificial intelligence to provide a more sophisticated understanding of human immunity and disease. An elite team of scientists are using AI to compile and assess the largest dataset of biomedicine to create superior models of immune system function and precision drug targeting, thus facilitating diagnosis and treatment of disease.
Immunis, Inc. Chairman, Dr. Hans Keirstead, presented at the 2022 Festival of Biologics Conference in Basel, Switzerland. The Festival of Biologics is a leading international event for drug discovery, development, manufacturing and marketing for clinical trials. Please enjoy these photos from the event.
Immunis Featured in NEO.LIFE Magazine
Immunis Inc was featured in an article by NEO.LIFE magazine entitled, "Sarcopenia: What a waste." NEO.LIFE was founded by Jane Metcalfe, the co-founder and former president or Wired magazine.
Immunis Chairman Dr. Hans Keirstead Recognized as a Top Orange County Business Leader
Immunis, Inc., a private biotech company generating a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., was recognized as one of Orange County Business Journal’s OC 500, a list that includes the most influential individuals in Orange County. Honorees are selected on a merit basis after extensive evaluation and include top executives, government figures, philanthropists, and other civic representatives who contribute to the community of business.
Immunis Chairman, Dr. Hans Keirstead, is the Board Chair of Mission Plasticos. Mission Plasticos is a non profit providing FREE reconstructive surgery to underserved populations in medical need. Please check out the segment from CBS2 News highlighting the importance of this life-changing work!
Immunis Chairman Dr. Hans Keirstead Meets With His Holiness the Dalai Lama [photos]
Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman, renowned neuroscientist Hans Keirstead, Ph.D., visited the Dalai Lama again this past week in His home in Dharamsala, India. The Dalai Lama remains a symbol of the unifying philosophy of Buddhism, where He is respected internationally as an educator of harmony and happiness for humanity.
Immunis Inc. Chairman, Dr. Hans Keirstead, presented a keynote at the 2022 Aging and Gerontology Conference in Dubai. Please enjoy the video footage of his keynote.
Immunis Chairman Dr. Hans Keirstead Presents at the Rejuvenation Startup Summit in Berlin [photos]
Immunis Inc Chairman, Dr. Hans Keirstead, delivered an exciting presentation about the potential of IMM01-STEM at the 2022 Rejuvenation Startup Summit in Berlin, Germany. The Immunis team is thrilled to share the following images of Dr. Keirstead in action.
Immunis, Inc., a private biotech company creating an innovative treatment for age and disease-related immune decline, announces that its Chairman Hans Keirstead, Ph.D. will deliver the keynote address at the Festival of Biologics Conference in Basel, Switzerland. The Festival of Biologics is one of the leading international events for drug discovery, development, manufacturing, pricing and market access for clinical trials.
Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman Hans Keirstead, Ph.D. will present the keynote address at the Aging and Gerontology Conference in Dubai. The Aging and Gerontology Conference is a renowned international event that brings together longevity entrepreneurs, pharma and biotech companies, investors, researchers, and government organizations with the goal of extending human health span.
Immunis Chairman Dr. Hans Keirstead to Present at the Rejuvenation Startup Summit in Berlin
Immunis, Inc., a private biotech company producing a novel treatment for age and disease-related immune decline, announces that its Chairman Hans Keirstead, Ph.D. will deliver a presentation on the main stage at the 2022 Rejuvenation Startup Summit (RSS) in Berlin, Germany. The Rejuvenation Startup Summit is a leading networking event for translational researchers, rejuvenation startups and longevity investors.
Immunis, Inc., a private biotech company generating an innovative treatment for age and disease-related immune decline, announces that its Chairman, Dr. Hans Keirstead, delivered a keynote on behalf of the National Institute of Child Sexual Assault (NICSA) at the UN General Assembly in New York City. As part of Immunis’ ongoing Corporate Social Responsibility Program, Dr. Keirstead presented a keynote on child sexual assault (CSA), which aligns with the United Nation’s efforts to eradicate human trafficking and eliminate emotional, economical and physical violence against children and women.
Immunis Welcomes Dr. Peter Diamandis to the Executive Advisory Board
Immunis Inc., a private biotechnology company developing an immunomodulatory secretome for age and disease-related immune decline in Phase 1/2a testing, welcomes Peter H. Diamandis, M.D. to the Executive Advisory Board. Dr. Diamandis received degrees in molecular genetics and aerospace engineering from MIT and is a Harvard-trained physician. His entrepreneurship has led to the creation of over 25 companies in the areas of space, education, venture capital and longevity.
Immunis, Inc., a private biotech company producing a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., delivered a keynote to the United Nations (UN) as part of the AI for Good Global Summit. AI for Good is a digital platform helping innovators become educated in building and identifying practical AI solutions for the advancement of the UN’s “Sustainable Development Goals.”
Immunis Chairman Dr. Hans Keirstead Is Awarded Innovator of the Year [photo]
Immunis, Inc., a private biotech company developing a novel immunomodulatory secretome for age and disease-related immune degeneration, congratulates its Chairman, Hans Keirstead, Ph.D., on being recognized as the Orange County Business Journal’s 2022 Innovator of the Year. This annual award highlights the greatest innovators of Orange County who have generated groundbreaking products, treatments, services and business models.
Immunis Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, initiates patient enrollment for their Phase 1/2a clinical trial to assess Immunis’ immunomodulatory secretome product, IMM01-STEM, in patients with muscle atrophy. Up to 18 patients ages 50-75 will participate in the clinical trial conducted at the University of California Irvine Medical Center, UCI Health, a facet of the California Institute of Regenerative Medicine (CIRM) Alpha Stem Cell Clinics Network.
Immunis Signs Clinical Trial Agreement with CIRM Alpha Stem Cell Clinics
Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, has formally signed a clinical trial agreement with California Institute of Regenerative Medicine (CIRM) Alpha Stem Cell Clinics Network to initiate STEM-MYO Phase 1/2a clinical trials. The trials will assess the safety and tolerability of Immunis’ immunomodulatory secretome product, IMM01-STEM, in patients with muscle atrophy related to knee osteoarthritis, an inflammatory disease that is a leading cause of disability in elderly adults.
Immunis Publishes Research Study Showing Reversal of Aged Muscle Deficits
Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, announced today the peer-reviewed publication of a research study conducted by Professor Micah J. Drummond at the University of Utah investigating the efficacy of Immunis’ immunomodulatory secretome product on aged skeletal muscle. The results were described in a GeroScience publication entitled “Reversal of deficits in aged skeletal muscle during disuse and recovery in response to treatment with a secretome product derived from partially differentiated human pluripotent stem cells.”
Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, today announced that the U.S. Food and Drug Administration has approved it’s Investigational New Drug application for a Phase 1/2a clinical trial investigating IMM01-STEM in participants with muscle atrophy: https://clinicaltrials.gov/ct2/show/NCT05211986
Immunis Closes $10 Million Financing Round
Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, has closed a $10M Series A First Closing financing led by Remiges Ventures with participation by several other healthcare investment firms. Strategic investor, Continuum Health Ventures, which supports thesis-driven startups at the intersection of health and technology in the digital health and longevity sectors, also joined the round. Proceeds will support clinical assessment of Immunis’ immunomodulatory secretome product in an FDA-awarded Phase 1/2a clinical trial targeting muscle atrophy, which is an age, disuse and disease-associated condition experienced by 100% of the population.
May 2022 FDA awards Phase 1/2a clinical trial to study the effects of Immunis’ platform immunomodulatory product STEM on muscular atrophy in patients with knee osteoarthritis